CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 163 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,371,377 | -10.5% | 49,832 | +10.3% | 0.00% | 0.0% |
| Q2 2023 | $1,532,482 | -30.3% | 45,166 | -26.1% | 0.00% | 0.0% |
| Q1 2023 | $2,197,586 | -16.5% | 61,078 | +4.1% | 0.00% | -50.0% |
| Q4 2022 | $2,633,050 | +71.0% | 58,651 | +7.7% | 0.00% | +100.0% |
| Q3 2022 | $1,539,670 | +11.7% | 54,464 | +8.6% | 0.00% | 0.0% |
| Q2 2022 | $1,378,913 | -36.9% | 50,133 | -21.1% | 0.00% | 0.0% |
| Q1 2022 | $2,186,828 | +142.2% | 63,511 | +172.7% | 0.00% | 0.0% |
| Q4 2021 | $903,000 | -28.4% | 23,286 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $1,262,000 | +70.5% | 23,379 | +5.6% | 0.00% | 0.0% |
| Q2 2021 | $740,000 | – | 22,135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |